Tag: REDLAMP

REDLAMP 5: Rituximab vs. Watch & Wait Approach in Patients with Advanced Follicular Lymphoma

Conventional therapy for patients with advanced stage, low tumor burden follicular lymphoma can include watchful waiting until the disease progresses. In this video Dr. Kelly Trevino explains the findings of a study in Lancet Oncology that assessed the difference in quality of life for patients who used rituximab to delay chemotherapy treatment and those patients who took the watchful wait approach.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

REDLAMP 4: Circulating Tumor DNA & CT Monitoring for Untreated DLBCL – A Correlative Biomarker Study

First-line chemotherapy for diffuse large B-cell lymphoma is given with curative intent, but is not always effective. In this video, Dr. Peter Martin discusses the implications of a recently published study in Lancet Oncology, which aimed to discover whether a blood test capable of detecting circulating tumor DNA might predict treatment success or failure. In the future, blood tests may be added to, or even replace, current standard surveillance methods like CT scans or PET scans.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

REDLAMP 3: Bortezomib-Based Therapy for Newly Diagnosed Mantle Cell Lymphoma

In a recent publication from the New England Journal of Medicine researchers presented results from an investigation into whether the substitution of bortezomib for vincristine in R-CHOP improved patient outcomes for patients newly diagnosed with mantle cell lymphoma. Mantle cell lymphoma is an unusual lymphoma that engenders much debate as to what treatments should be used in patient care. In the below video Dr. John Leonard discusses the efficacy of substituting bortezomib for vincristine in R-CHOP and how this could improve the outcomes in patients with newly diagnosed mantle cell lymphoma.

You can follow Lymphoma Program Director John Leonard @JohnPLeonardMD.

The previous entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

%d bloggers like this: